The PI3K inhibitor ME-401 +/- rituximab in relapsed/refractory (R/R) follicular lymphoma (FL), chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) Meeting Abstract
| Authors: | Pagel, J.; Zelenetz, A.; Reddy, N.; Jagadeesh, D.; Stathis, A.; Salman, H.; Soumerai, J.; Kenkre, V.; Asch, A.; Jhangiani, H.; Llorin-Sangalang, J.; Wood, J.; Gorbatchevsky, I. |
| Abstract Title: | The PI3K inhibitor ME-401 +/- rituximab in relapsed/refractory (R/R) follicular lymphoma (FL), chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) |
| Meeting Title: | 2019 Lymphoma and Myeloma Congress |
| Journal Title: | American Journal of Hematology |
| Volume: | 94 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2019 Oct 23-26 |
| Meeting Location: | New York, NY |
| ISSN: | 0361-8609 |
| Publisher: | John Wiley & Sons, Inc. |
| Date Published: | 2019-11-01 |
| Start Page: | S32 |
| Language: | English |
| ACCESSION: | WOS:000491489200050 |
| PROVIDER: | wos |
| PUBMED: | 31621937 |
| DOI: | 10.1002/ajh.25639 |
| Notes: | Meeting Abstract: P-049 -- Source: Wos |
